S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:HOLX

Hologic (HOLX) Stock Price, News & Analysis

$77.35
+1.18 (+1.55%)
(As of 03/27/2024 ET)
Today's Range
$76.46
$77.37
50-Day Range
$72.04
$77.35
52-Week Range
$64.02
$87.88
Volume
1.27 million shs
Average Volume
1.78 million shs
Market Capitalization
$18.16 billion
P/E Ratio
36.66
Dividend Yield
N/A
Price Target
$86.89

Hologic MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
12.3% Upside
$86.89 Price Target
Short Interest
Healthy
2.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.39mentions of Hologic in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.47 M Sold Last Quarter
Proj. Earnings Growth
8.46%
From $4.02 to $4.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

100th out of 939 stocks

X-Ray Apparatus & Tubes Industry

1st out of 4 stocks

HOLX stock logo

About Hologic Stock (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Stock Price History

HOLX Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Hologic to Unveil Groundbreaking AI Research at ECR 2024
Hologic to Unveil Groundbreaking AI Research at ECR 2024
Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)
HOLX Mar 2024 50.000 put
HOLX Mar 2024 70.000 put
Hologic, Inc.
Hologic: Prospects For Growth As Headwinds Disappear
See More Headlines
Receive HOLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
3/27/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
X - ray apparatus & tubes
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:HOLX
CUSIP
43644010
Employees
6,990
Year Founded
1985

Price Target and Rating

Average Stock Price Target
$86.89
High Stock Price Target
$105.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+12.3%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$456 million
Pretax Margin
15.83%

Debt

Sales & Book Value

Annual Sales
$4.03 billion
Cash Flow
$5.46 per share
Book Value
$20.48 per share

Miscellaneous

Free Float
230,624,000
Market Cap
$18.16 billion
Optionable
Optionable
Beta
1.00

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Hologic was last updated on Tuesday, March 26, 2024 at 10:59 PM.

Pros

Here are some ways that investors could benefit from investing in Hologic, Inc.:

  • Hologic has seen significant growth in institutional investments, indicating confidence from major financial entities like Macquarie Group Ltd. and Norges Bank.
  • Recent analyst upgrades, such as the "outperform" rating from William Blair, suggest positive sentiment towards the company's performance and potential.
  • The company offers a diverse range of products in women's health, including advanced diagnostic assays and surgical solutions, catering to a crucial market segment.
  • Continuous innovation in products like the Aptima SARS-CoV-2 assay and the MyoSure Hysteroscopic Tissue Removal System keeps Hologic competitive in the healthcare equipment industry.
  • With a consensus target price of $86.89, there is potential for stock price appreciation, making it an attractive investment opportunity.

Cons

Investors should be bearish about investing in Hologic, Inc. for these reasons:

  • Despite positive ratings, some analysts have downgraded Hologic's stock, like the shift from a "buy" to a "hold" rating by StockNews.com, which may raise concerns about future performance.
  • While the company has a strong presence in women's health products, market competition in the healthcare equipment sector is intense, potentially impacting Hologic's market share.
  • Fluctuations in the healthcare industry, regulatory changes, or unexpected events like pandemics can influence the demand for Hologic's products, leading to uncertainties in revenue streams.
  • Investors need to consider the high institutional ownership of Hologic's stock, which can sometimes lead to increased volatility or limited control over decision-making processes.
  • Any disruptions in the supply chain, manufacturing processes, or regulatory approvals could affect Hologic's ability to deliver products, impacting financial performance.

HOLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Hologic stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
View HOLX analyst ratings
or view top-rated stocks.

What is Hologic's stock price target for 2024?

8 equities research analysts have issued 1-year target prices for Hologic's shares. Their HOLX share price targets range from $72.00 to $105.00. On average, they predict the company's share price to reach $86.89 in the next twelve months. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for HOLX
or view top-rated stocks among Wall Street analysts.

How have HOLX shares performed in 2024?

Hologic's stock was trading at $71.45 at the beginning of the year. Since then, HOLX shares have increased by 8.3% and is now trading at $77.35.
View the best growth stocks for 2024 here
.

Are investors shorting Hologic?

Hologic saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 4,650,000 shares, a drop of 15.0% from the February 29th total of 5,470,000 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is presently 2.6 days. Currently, 2.0% of the shares of the stock are sold short.
View Hologic's Short Interest
.

When is Hologic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our HOLX earnings forecast
.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings results on Thursday, February, 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.95 by $0.03. The medical equipment provider had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $989.32 million. Hologic had a net margin of 12.98% and a trailing twelve-month return on equity of 18.91%. The company's revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.07 EPS.
Read the conference call transcript
.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY 2024 earnings guidance on Thursday, February, 1st. The company provided EPS guidance of 3.970-4.120 for the period, compared to the consensus earnings per share estimate of 4.000. The company issued revenue guidance of $4.0 billion-$4.1 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Steve MacMillan's approval rating as Hologic's CEO?

447 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among the company's employees. 81.0% of employees surveyed would recommend working at Hologic to a friend.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.79%), Vanguard Group Inc. (11.79%), Victory Capital Management Inc. (2.15%), Price T Rowe Associates Inc. MD (1.51%), Norges Bank (1.30%) and Parnassus Investments LLC (1.23%). Insiders that own company stock include Benjamin Jordan Cohn, Charles J Dockendorff, Essex D Mitchell, Jan Verstreken, John M Griffin, Karleen Marie Oberton, Scott T Garrett, Sean S Daugherty and Sean S Daugherty.
View institutional ownership trends
.

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Hologic have any subsidiaries?
The following companies are subsidiares of Hologic: Acessa Health, Acessa Health Inc., Beijing Hologic Technology Co. Ltd., Benassar Diagnostica-Equipamientos Medicos Unipessoal Lda., BioLucent, BioLucent LLC, Bioptics Inc., Biotheranostics Inc, Biotheranostics Inc., Bolder Surgical, Cynosure, Cytyc, Cytyc Corporation, Cytyc Prenatal Products Corp., Cytyc Surgical Products LLC, Diagenode Co. Ltd., Diagenode LLC, Diagenode SA, Diagenode SA., Diagenode SPA, Direct Radiography Corp., Emsor Sociedad de responsabilidad limitada, Faxitron Bioptics, Faxitron Bioptics LLC, Focal Therapeutics, Gen-Probe, Gen-Probe Incorporated, Gen-Probe Prodesse Inc., Gen-Probe Sales & Service Inc., Genewave SAS, Health Beacons Inc, Health Beacons Inc., Hologic (Australia & New Zealand) Pty Ltd., Hologic (MA) LLC, Hologic (Shanghai) Medical Supplies Co. Ltd., Hologic ASE LLC, Hologic Asia Limited, Hologic Asia Pacific Limited, Hologic Austria GmbH, Hologic BV, Hologic Bermuda Limited, Hologic Canada ULC, Hologic Caribbean (Barbados) SRL, Hologic Denmark ApS, Hologic Deutschland GmbH, Hologic Espana S.A., Hologic Finance Ltd., Hologic France SARL, Hologic GGO 2 LLC, Hologic GGO 3 LLP, Hologic GGO 4 LTD, Hologic Global Holding LTD, Hologic HUB LTD, Hologic Hitec-Imaging, Hologic Hitec-Imaging GmbH, Hologic Holdings Limited, Hologic IP LTD, Hologic Iberia S.L., Hologic India LLP, Hologic International Holdings B.V., Hologic Ireland Limited, Hologic Italia S.r.l., Hologic Japan KK, Hologic Latin America (Servicos Em Marketing E Negocios) Ltda., Hologic Ltd., Hologic Malaysia SDN. BHD., Hologic Medical Technologies (Beijing) Co. Ltd., Hologic Medicor GmbH, Hologic Medicor Suisse GmbH, Hologic Netherlands B.V., Hologic Nordic Holdings Oy, Hologic Singapore Pte. Ltd, Hologic Suisse SA, Hologic Surgical Products Costa Rica S.R.L., Hologic Sweden AB, Hologic Taiwan Ltd., Hologic UK Finance Ltd., Hologic US Finance Co LLC, Interlace Medical, Mobidiag Oy, Mobidiag Oy., Mobidiag UK Ltd., NXT-Dx SCRL, Navigation Three Limited, R2 Technology, Sentinelle Medical, Somatex (HK) Limited, Somatex Medical Technologies GmbH, Somatex Medical Technologies GmbH., Somatex USA Inc., SuperSonic Imagine (Shanghai) Medical Devices Co. Ltd., SuperSonic Imagine GmbH, SuperSonic Imagine HK Ltd, SuperSonic Imagine Ltd, SuperSonic Imagine SA, SuperSonic Imagine Srl, Suros Surgical Systems, Suros Surgical Systems Inc., TCT International, TCT International Co. Ltd., Third Wave Technologies, and Tridaho LLC.
Read More
This page (NASDAQ:HOLX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners